NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $506,338 | -44.1% | 850,130 | -46.0% | 0.00% | – |
| Q2 2023 | $905,142 | -30.3% | 1,573,614 | -14.8% | 0.00% | – |
| Q1 2023 | $1,298,555 | -65.0% | 1,847,425 | +12.4% | 0.00% | – |
| Q4 2022 | $3,713,722 | -49.6% | 1,643,239 | -28.6% | 0.00% | -100.0% |
| Q3 2022 | $7,369,000 | -15.3% | 2,302,854 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $8,702,000 | -4.1% | 2,290,262 | +36.1% | 0.00% | 0.0% |
| Q1 2022 | $9,070,000 | -55.3% | 1,682,834 | +12.2% | 0.00% | -66.7% |
| Q4 2021 | $20,269,000 | +30.3% | 1,500,367 | +73.3% | 0.00% | +50.0% |
| Q3 2021 | $15,551,000 | +90.0% | 865,858 | +81.5% | 0.00% | +100.0% |
| Q2 2021 | $8,186,000 | -21.2% | 477,014 | -8.1% | 0.00% | -50.0% |
| Q1 2021 | $10,384,000 | +31.7% | 519,131 | +12.0% | 0.00% | +100.0% |
| Q4 2020 | $7,884,000 | +17.5% | 463,686 | +14.7% | 0.00% | 0.0% |
| Q3 2020 | $6,709,000 | -24.8% | 404,354 | +5.0% | 0.00% | -50.0% |
| Q2 2020 | $8,919,000 | -26.7% | 385,099 | -43.5% | 0.00% | -33.3% |
| Q1 2020 | $12,170,000 | -2.4% | 681,764 | +18.0% | 0.00% | 0.0% |
| Q4 2019 | $12,467,000 | +35.6% | 577,592 | +14.5% | 0.00% | +50.0% |
| Q3 2019 | $9,192,000 | -43.3% | 504,591 | +10.8% | 0.00% | -50.0% |
| Q2 2019 | $16,210,000 | -41.5% | 455,607 | -44.8% | 0.00% | -50.0% |
| Q1 2019 | $27,710,000 | -39.7% | 824,666 | -41.0% | 0.01% | -42.9% |
| Q4 2018 | $45,982,000 | -41.5% | 1,398,908 | +8.5% | 0.01% | -30.0% |
| Q3 2018 | $78,622,000 | +33.9% | 1,289,740 | +7.2% | 0.02% | +25.0% |
| Q2 2018 | $58,734,000 | -56.7% | 1,202,818 | -5.8% | 0.02% | -57.9% |
| Q1 2018 | $135,745,000 | +203.3% | 1,277,485 | +70.5% | 0.04% | +216.7% |
| Q4 2017 | $44,751,000 | +165.2% | 749,353 | +6.6% | 0.01% | +140.0% |
| Q3 2017 | $16,873,000 | +30.3% | 703,045 | +6.1% | 0.01% | +25.0% |
| Q2 2017 | $12,948,000 | -53.5% | 662,350 | -44.2% | 0.00% | 0.0% |
| Q1 2017 | $27,834,000 | +7.1% | 1,186,020 | -44.0% | 0.00% | 0.0% |
| Q4 2016 | $25,988,000 | +154.0% | 2,117,936 | +255.7% | 0.00% | +33.3% |
| Q3 2016 | $10,231,000 | +49.8% | 595,478 | +24.1% | 0.00% | +50.0% |
| Q2 2016 | $6,829,000 | -2.4% | 479,963 | -5.7% | 0.00% | -33.3% |
| Q1 2016 | $6,995,000 | -14.4% | 508,717 | +4.9% | 0.00% | 0.0% |
| Q4 2015 | $8,175,000 | +47.0% | 485,173 | -4.4% | 0.00% | +50.0% |
| Q3 2015 | $5,561,000 | -16.7% | 507,489 | -4.9% | 0.00% | 0.0% |
| Q2 2015 | $6,673,000 | +9.0% | 533,415 | -4.1% | 0.00% | 0.0% |
| Q1 2015 | $6,121,000 | -28.5% | 556,436 | +0.8% | 0.00% | -33.3% |
| Q4 2014 | $8,557,000 | +27.2% | 552,087 | -1.0% | 0.00% | 0.0% |
| Q3 2014 | $6,729,000 | -16.6% | 557,428 | -11.4% | 0.00% | 0.0% |
| Q2 2014 | $8,070,000 | +1.3% | 629,389 | -4.2% | 0.00% | 0.0% |
| Q1 2014 | $7,966,000 | -8.7% | 657,293 | -14.5% | 0.00% | -25.0% |
| Q4 2013 | $8,724,000 | +47.5% | 768,648 | +35.7% | 0.00% | +33.3% |
| Q3 2013 | $5,915,000 | +8.2% | 566,284 | +19.7% | 0.00% | 0.0% |
| Q2 2013 | $5,466,000 | – | 473,222 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |